Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Immunovant, Inc. | Director, 10%+ Owner | Common Stock, $0.0001 par value per share | 79.8M | $3.03B | $38.00 | Oct 2, 2023 | Direct |
Arbutus Biopharma Corp | 10%+ Owner | Common shares, without par value | 38.8M | Oct 18, 2021 | Direct | ||
Arbutus Biopharma Corp | 10%+ Owner | Series A participating convertible preferred shares | 0 | Oct 18, 2021 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
IMVT | Immunovant, Inc. | Oct 2, 2023 | 2 | $228M | 4 | Oct 4, 2023 | Director, 10%+ Owner |
IMVT | Immunovant, Inc. | Oct 6, 2022 | 1 | $2.5M | 4 | Oct 7, 2022 | 10%+ Owner |
ABUS | Arbutus Biopharma Corp | Oct 18, 2021 | 2 | $0 | 4 | Oct 20, 2021 | 10%+ Owner |
IMVT | Immunovant, Inc. | Aug 2, 2021 | 1 | $0 | 4 | Aug 2, 2021 | 10%+ Owner |